AC
CSCI

Armistice Capital’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Armistice Capital’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,800
Closed -$494K – 86
2019
Q3 		$494K Buy
+4,800
New +$1.04M 0.03% 65

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Armistice Capital's CSCI Position: Q4 2019 in Review

Armistice Capital sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2019, closing a stake of 4,800 shares — an estimated $494K sold.

Armistice Capital first reported a position in CSCI in Q3 2019 and held it in 1 quarter. The position peaked at $494K in Q3 2019. 24 funds tracked by Wall St. Rank hold CSCI as of Q4 2019.

  • Armistice Capital reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Armistice Capital sold 4,800 COSCIENS Biopharma Inc. Common Stock shares in Q4 2019, an estimated $494K.
  • Armistice Capital first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Armistice Capital's COSCIENS Biopharma Inc. Common Stock position peaked at $494K in Q3 2019.
  • 24 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2019.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.